Projects per year
Personal profile
Biography
Professor Howard Gurney is the Director of Clinical Trials for the Faculty of Medicine and Health Sciences at Macquarie University.
Professor Gurney has a firm background in clinical research and has subspecialty interests in urogenital cancers including prostate, bladder, testis and kidney cancer.
He has been the principal investigator for over 100 clinical trials and has published over 100 peer-reviewed articles in journals and book chapters. Current research interests include the pharmacogenomics and therapeutic monitoring of chemotherapy and targeted therapies and he has published widely in this area. He is regarded as a leading authority on mechanisms for safe dosing of anticancer agents and has held research grants and has written a number of invited editorials on these topics.
Fingerprint Dive into the research topics where Howard Gurney is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 6 Similar Profiles
Prostatic Neoplasms
Medicine & Life Sciences
Renal Cell Carcinoma
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Drug Therapy
Medicine & Life Sciences
Castration
Medicine & Life Sciences
Neoplasms
Medicine & Life Sciences
docetaxel
Medicine & Life Sciences
Survival
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2013 2024
A phase 1/2 open label, multi-center dose escalation and expansion study of combination immunotherapy CBT-501 (anti-PD-1) or nivolumab with CBT-101 (c-Met inhibitor) in locally advanced or metastatic hepatocellular carcinoma and renal cell carcinoma
Sabanathan, D., Chapman, N., Butala, R. & Gurney, H.
16/05/19 → 15/05/24
Project: Other › Sponsored clinical trial
MISC_UniCanberra: Research into and Testing of Epigenetic based Biomarkers and companion therapeutics.
Gurney, H. & Cunningham, J.
1/04/19 → 30/04/20
Project: Other › Sponsored clinical trial
MISC_UniCanberra: Research into and Testing of Epigenetic based Biomarkers and companion therapeutics.
Gurney, H. & Cunningham, J.
1/04/19 → 30/04/20
Project: Other › Sponsored clinical trial
A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined with Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients with Previously Untreated Advanced Renal Cell Carcinoma
Gurney, H., Chapman, N. & Butala, R.
28/02/19 → 27/02/24
Project: Other › Sponsored clinical trial
Misc_Novotech: A Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Study Comparing CB‐839 in Combination with Cabozantinib (CB‐Cabo) vs. Placebo with Cabozantinib (Pbo‐Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
Gurney, H. & Cunningham, J.
17/07/18 → 5/06/23
Project: Other › Sponsored clinical trial
Research Outputs 1987 2019
Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy?
Lee, C. I., Fox, P., Balakrishnar, B., Balleine, R. L., Gao, B., Provan, P., Coulter, S., Liddle, C., Hui, R., Wong, M., Gurney, H. & Wilcken, N., 1 Aug 2019, In : Breast. 46, p. 52-57 6 p.Research output: Contribution to journal › Article › Research › peer-review
Hot Flashes
Tamoxifen
Cytochrome P-450 CYP2D6
4-hydroxy-N-desmethyltamoxifen
Compliance
Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment
Attard, G., Borre, M., Gurney, H., Loriot, Y., Andresen-Daniil, C., Kalleda, R., Pham, T., Taplin, M. E. & on behalf of PLATO collaborators, 1 Sep 2018, In : Journal of Clinical Oncology. 36, 25, p. 2639-2646 8 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access
File
Castration
Prostate-Specific Antigen
Prostatic Neoplasms
Prednisone
Control Groups
Cardiovascular toxicity of targeted therapies for cancer: a protocol for an overview of systematic reviews
Van Leeuwen, M. T., Luu, S., Gurney, H., Brown, M. R., Webber, K., Pearson, S-A., Hunt, L. & Vajdic, C. M., 1 Jun 2018, In : BMJ Open. 8, 6, p. 1-6 6 p., e021064.Research output: Contribution to journal › Review article › Research › peer-review
Open Access
File
Ethics
Embolism and Thrombosis
Cerebrovascular Disorders
Neoplasms
Peer Review
Early detection of cardiotoxicity in cancer patients receiving novel chemotherapy and immunomodulation by measuring global longitudinal strain (GLS) with transthoracic echocardiography
Al-zubaidi, K., Brown, M., Gurney, H., Kefford, R. & Poursoltan, P., 2 Sep 2018, In : Heart Lung and Circulation. 27, Supplement 2, p. S94 1 p., 0115.Research output: Contribution to journal › Article › Research › peer-review
Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer
Gao, B., Lu, Y., Nieuweboer, A. J. M., Xu, H., Beesley, J., Boere, I., De Graan, A. J. M., De Bruijn, P., Gurney, H., Kennedy, C. J., Chiew, Y. E., Johnatty, S. E., Beale, P., Harrison, M., Luccarini, C., Conroy, D., Mathijssen, R. H. J., Harnett, P. R., Balleine, R. L., Chenevix-Trench, G. & 2 others, 1 Dec 2018, In : Scientific Reports. 8, 1, p. 1-10 10 p., 1508.Research output: Contribution to journal › Article › Research › peer-review
Open Access
File
Genome-Wide Association Study
Carboplatin
Paclitaxel
Single Nucleotide Polymorphism
Drug Therapy